EGLN1/PHD2 Antibody (2445D) - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-80714
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human, Mouse
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Rabbit Clone # 2445D
Format
Azide and BSA Free
Concentration
1 mg/ml
Product Summary for EGLN1/PHD2 Antibody (2445D) - Azide and BSA Free
Immunogen
This EGLN1/PHD2 antibody was developed against S. frugiperda insect ovarian cell line Sf 21-derived recombinant human EGLN1/PHD2 protein (amino acids 2-426) [UniProt #Q9QZT9].
Clonality
Monoclonal
Host
Rabbit
Theoretical MW
46 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for EGLN1/PHD2 Antibody (2445D) - Azide and BSA Free
Western Blot: EGLN1/PHD2 Antibody (2445D)Azide and BSA Free [NBP2-80714]
Western Blot: EGLN1/PHD2 Antibody (2445D) - Azide and BSA Free [NBP2-80714] - Western blot shows lysates of PC3 human prostate cancer cell line, HEK293T human embryonic kidney cell line, and NIH3T3 mouse embryonic fibroblast cell line. PVDF membrane was probed with 1 ug/mL of Rabbit Anti-Human/Mouse EGLN1/PHD2 Monoclonal Antibody (Catalog # NBP2-78782) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for EGLN1/PHD2 at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions. Image from the standard format of this antibody.Immunohistochemistry: EGLN1/PHD2 Antibody (2445D) - Azide and BSA Free [NBP2-80714]
Immunohistochemistry: EGLN1/PHD2 Antibody (2445D) - Azide and BSA Free [NBP2-80714] - EGLN1/PHD2 was detected in immersion fixed paraffin-embedded sections of human kidney using Rabbit Anti-Human/Mouse EGLN1/PHD2 Monoclonal Antibody (Catalog # NBP2-78782) at 3 ug/mL for 1 hour at room temperature followed by incubation with an anti-rabbit secondary antibody.Applications for EGLN1/PHD2 Antibody (2445D) - Azide and BSA Free
Application
Recommended Usage
Immunohistochemistry
3 - 25 ug/mL
Immunohistochemistry-Paraffin
3 - 25 ug/mL
Western Blot
1 ug/mL
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
PBS
Format
Azide and BSA Free
Preservative
No Preservative
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
Background: EGLN1/PHD2
EGLN1/PHD2 has been implicated in several critical processes including erythropoiesis, angiogenesis, and metabolism as well as various pathologies such as cancer (2, 5, 6). Studies in mice have found that somatic deletion of PHD2 resulted in higher vascular endothelial growth factor A (VEGF-A) levels, increased blood vessel formation, and more erythropoietin (EPO), leading to severe polycythemia or erythrocytosis (high red blood cell (RBC) volume) (6). Another study revealed that specific point mutations in EGLN1/PHD2 led to elevated EPO and RBC mass associated with hemorrhages and strokes (6). Accordingly, given the known role of PHD2 in inhibition of EPO production, PHD2 inhibitors are being studied as a potential therapeutic for anemia (6). Additionally, dysregulation in EGLN1, and specifically the PHD2-VHL-HIF-1alpha pathway, has been associated with the development of pheochromocytomas (PCC) and sympathetic paragangliomas (PGL), which are rare neuroendocrine tumors (2). Besides pathological features, EGLN1/PHD2 may also be important for high altitude adaptation as two coding sequence variants in PHD2 are prevalent in the Tibetan population but is very rare in people at lower altitudes (2).
Alternate names for EGLN1/PHD2 include HIF Prolyl Hydroxylase 2, PH2, Prolyl hydroxylase domain containing protein 2, HIF2PH2, HIF-Prolyl hydroxylase 2, egl nine homolog 1, and C1orf12.
References
1. Amorim-Pires, D., Peixoto, J., & Lima, J. (2016). Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas. Cytogenetic and genome research. https://doi.org/10.1159/000457479
2. Gardie, B., Percy, M. J., Hoogewijs, D., Chowdhury, R., Bento, C., Arsenault, P. R., Richard, S., Almeida, H., Ewing, J., Lambert, F., McMullin, M. F., Schofield, C. J., & Lee, F. S. (2014). The role of PHD2 mutations in the pathogenesis of erythrocytosis. Hypoxia (Auckland, N.Z.). https://doi.org/10.2147/HP.S54455
3. Minervini, G., Quaglia, F., & Tosatto, S. C. (2015). Insights into the proline hydroxylase (PHD) family, molecular evolution and its impact on human health. Biochimie. https://doi.org/10.1016/j.biochi.2015.07.009
4. Semenza G. L. (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. Science's STKE : signal transduction knowledge environment. https://doi.org/10.1126/stke.4072007cm8
5. Chan, D. A., & Giaccia, A. J. (2010). PHD2 in tumour angiogenesis. British journal of cancer. https://doi.org/10.1038/sj.bjc.6605682
6. Meneses, A. M., & Wielockx, B. (2016). PHD2: from hypoxia regulation to disease progression. Hypoxia (Auckland, N.Z.). https://doi.org/10.2147/HP.S53576
Long Name
Egl Nine Homolog 1/Prolyl Hydroxylase Domain-containing Protein 2
Alternate Names
C1orf12, HIFPH2, HPH2, PHD2, SM20, ZMYND6
Gene Symbol
EGLN1
Additional EGLN1/PHD2 Products
Product Documents for EGLN1/PHD2 Antibody (2445D) - Azide and BSA Free
Product Specific Notices for EGLN1/PHD2 Antibody (2445D) - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...